Specialty Pharmacy Times
Generic Pharmacy Report
Directions in Pharmacy
Health Care Reform
Acute Coronary Syndrome
Medication Therapy Management
Type 2 Diabetes
Vitamins and Supplements
News & Views
Compounding in the Kitchen
Piller of the Community
Focus on Current Thinking
The Reinvented Pharmacist
Pharmacists United for Truth and Transparency
For the Record
OTC Guide App
PharmacyTimes Augmented Reality
Next-Generation Pharmacist™ Videos
Videos | Page 11
Rationale for Categorizing Hydrocodone Combination Products as Schedule III
Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
Will Rescheduling Hydrocodone Combination Products Actually Reduce Abuse?
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.
Effect of Beta-Blockers on Mortality after Myocardial Infarction in Adults with COPD
Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.
Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
Martin R. Stämpfli, PhD, explains the development of COPD in his lecture at the seminar “COPD—Bridging the Gap between Science and Clinical Care.”
Keeping Pace with Racing Hearts: Get With the Guidelines—AFIB
An overview of “Get with the Guidelines – AFIB,” a quality-improvement program created by the American Heart Association for health care providers.
New Anticoagulants for Stroke Prevention in Atrial Fibrillation
Christian Ruff, MD, MPH, gives an overview of the anticoagulants currently available for prevention of stroke in patients with atrial fibrillation.
Atrial Fibrillation Research
Chris Cannon, MD, FACC, discusses 3 research papers on atrial fibrillation in this video produced by the American College of Cardiology.
Potential for Abuse of Hydrocodone Combination Products
Mary Lynn McPherson, PharmD, discusses the appeal of hydrocodone combination products to drug abusers.
Evidence for Rescheduling Hydrocodone Combination Products?
Jeff Fudin, PharmD, FCCP, argues that there is no evidence to support categorizing hydrocodone combination products as Schedule II drugs rather than Schedule III drugs.
American Journal of Managed Care
American Journal of Pharmacy Benefits
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright HCPLive 2006-2013
Intellisphere, LLC. All Rights Reserved.